Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $727.2, ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Summit Therapeutics (SMMT – Research Report).

Truist Financial analyst Michael Ciarmoli maintained a Buy rating on Northrop Grumman (NOC – Research Report) today and set a price target of ...